Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Britannia Life SciencesBLSIF 3-Year EBITDA Growth Rate is 25.00% as of Mar. 2026, which is 17% below its 10-year median of 29.95. The stock has 5 warning signs investors should review. Among 1,127 Biotechnology companies, Britannia Life Sciences ranks better than 61.58% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 25.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Britannia Life Sciences was 34.90% per year. The lowest was 25.00% per year. And the median was 29.95% per year.
Britannia Life Sciences (OTCPK:BLSIF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Britannia Life Sciences 3-Year EBITDA Growth Rate Related Terms
BLSIF vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Britannia Life Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Britannia Life Sciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Britannia Life Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Britannia Life Sciences's 3-Year EBITDA Growth Rate falls into.
Britannia Life Sciences 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 25.00% mean?
Britannia Life Sciences (BLSIF) has a 3-Year EBITDA Growth Rate of 25.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Britannia Life Sciences and its competitors. This is 17% below median its historical median of 29.95. Over the past decade, Britannia Life Sciences' 3-Year EBITDA Growth Rate has ranged from 25.00 to 34.90. According to the industry distribution chart, Britannia Life Sciences ranks #433 out of 1127 companies in the Biotechnology industry, placing it in the top 38.4%.
Is Britannia Life Sciences' 3-Year EBITDA Growth Rate too high?
Britannia Life Sciences' current 3-Year EBITDA Growth Rate of 25.00% is 17% below median its 10-year median of 29.95. Over the past 10 years, this metric has ranged from a low of 25.00 to a high of 34.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Britannia Life Sciences' value of 25.00% is 67.8% above this industry median. Based on the distribution chart, Britannia Life Sciences ranks #433 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint.
How does Britannia Life Sciences' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Britannia Life Sciences ranks #433 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts Britannia Life Sciences in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Britannia Life Sciences' value of 25.00% is 67.8% above this benchmark. Historically, Britannia Life Sciences' own 3-Year EBITDA Growth Rate has ranged from 25.00 to 34.90 over the past decade. While the company's 10-year median is 29.95 vs. the industry median of 14.90, Britannia Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Britannia Life Sciences's current 3-Year EBITDA Growth Rate of 25.00% is 67.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Britannia Life Sciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Britannia Life Sciences's current 3-Year EBITDA Growth Rate is 25.00%, which is 17% below median its own 10-year median of 29.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Britannia Life Sciences stock overvalued right now?
Britannia Life Sciences (BLSIF) has a current 3-Year EBITDA Growth Rate of 25.00%. The current 3-Year EBITDA Growth Rate is 25.00%, which is 17% below median its 10-year median of 29.95 and 67.8% above the Biotechnology industry median of 14.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Britannia Life Sciences (BLSIF), the current 3-Year EBITDA Growth Rate is 25.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Britannia Life Sciences Inc provides product testing, safety assessment, and manufacturing services to the cosmetic and consumer packaged goods industries in the United Kingdom and globally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLSIF has been successfully added to your 
